Toward Effective Long-Term Prevention of Thromboembolism: Novel Oral Anticoagulant Delivery Systems

Miha Homar; Mateja Cegnar; Miha Kotnik; Luka Peternel

doi:10.1055/s-0030-1248730

Seminars in Thrombosis and Hemostasis, Table of Contents

Semin Thromb Hemost 2010; 36(1): 113-122
DOI: 10.1055/s-0030-1248730

Toward Effective Long-Term Prevention of Thromboembolism: Novel Oral Anticoagulant Delivery Systems

Miha Homar¹ , Mateja Cegnar¹ , Miha Kotnik¹ , Luka Peternel¹

¹SDC Slovenia, Lek Pharmaceuticals d.d., Ljubljana, Slovenia

Abstract

ABSTRACT

Despite intensive research in the field of oral anticoagulants over the last decade, simple and effective long-term prevention of thromboembolism is still an unmet need. In addition to drug discovery approaches, the development of novel oral drug delivery systems (DDSs) of clinically well-established anticoagulants presents an intriguing mean of improvement of anticoagulant therapy. The latter topic is therefore the focus of the present review. All relevant clinical trials with anticoagulants formulated in the oral DDS are reviewed, and selected preclinical examples of promising novel anticoagulant DDSs are also described. For greater understanding, a background on DDS and drug absorption from the gastrointestinal tract is also provided. Three leading approaches for the oral anticoagulant DDS are currently being investigated in clinical settings, all relying on coadministration of anticoagulants with specific carriers. In contrast to the clinical setting, a diverse range of possibilities for oral delivery of anticoagulant are being investigated in preclinical trials (e.g., nanotechnology), and it would be therefore interesting to examine their performance in clinical trials.

KEYWORDS

Drug delivery systems - anticoagulants - oral delivery - absorption - gastrointestinal tract

Full Text

References

REFERENCES

1 Norman P. Antithrombotics: Will generics temper the strong sales trend? SPECTRUM therapy markets and emerging technologies antithrombotics. , Decision Resources 2006;
2 Hirsh J, Bauer K A, Donati M B, Gould M, Samama M M, Weitz J I. American College of Chest Physicians . Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 133(6, suppl) 141S-159S
3 Greinacher A, Warkentin T E. The direct thrombin inhibitor hirudin. Thromb Haemost. 2008; 99(5) 819-829
4 Walenga J M, Bounameaux H, Ikeda Y. Landmarks in anti-thrombin drug development: the argatroban story. Semin Thromb Hemost. 2007; 34 1-2
5 Ieko M. Dabigatran etexilate, a thrombin inhibitor for the prevention of venous thromboembolism and stroke. Curr Opin Investig Drugs. 2007; 8(9) 758-768
6 Laux V, Perzborn E, Kubitza D, Misselwitz F. Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitor. Semin Thromb Hemost. 2007; 33(5) 515-523
7 Agnelli G, Eriksson B I, Cohen A T EXTEND Study Group et al. Safety assessment of new antithrombotic agents: lessons from the EXTEND study on ximelagatran. Thromb Res. 2009; 123(3) 488-497
8 Kimmel S E. Warfarin therapy: in need of improvement after all these years. Expert Opin Pharmacother. 2008; 9(5) 677-686
9 Sobieraj-Teague M, O’Donnell M, Eikelboom J. New anticoagulants for atrial fibrillation. Semin Thromb Hemost. 2009; 35(5) 515-524
10 Levi M, Hobbs F D, Jacobson A K et al.. Improving antithrombotic management in patients with atrial fibrillation: current status and perspectives. Semin Thromb Hemost. 2009; 35(6) 527-542
11 Harenberg J. New anticoagulants in atrial fibrillation. Semin Thromb Hemost. 2009; 35(6) 574-585
12 Harenberg J. Development of new anticoagulants: present and future. Semin Thromb Hemost. 2008; 34(8) 779-793
13 Fareed J, Hoppensteadt D A, Fareed D et al.. Survival of heparins, oral anticoagulants, and aspirin after the year 2010. Semin Thromb Hemost. 2008; 34(1) 58-73
14 Harenberg J, Wehling M. Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa. Semin Thromb Hemost. 2008; 34(1) 39-57
15 Mousa S A. Heparin, low molecular weight heparin, and derivatives in thrombosis, angiogenesis, and inflammation: emerging links. Semin Thromb Hemost. 2007; 33(5) 524-533
16 Laux V, Perzborn E, Kubitza D, Misselwitz F. Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitor. Semin Thromb Hemost. 2007; 33(5) 515-523
17 Thomas V H, Bhattachar S, Hitchingham L et al.. The road map to oral bioavailability: an industrial perspective. Expert Opin Drug Metab Toxicol. 2006; 2(4) 591-608
18 Hurst S, Loi C M, Brodfuehrer J, El-Kattan A. Impact of physiological, physicochemical and biopharmaceutical factors in absorption and metabolism mechanisms on the drug oral bioavailability of rats and humans. Expert Opin Drug Metab Toxicol. 2007; 3(4) 469-489
19 Custodio J M, Wu C Y, Benet L Z. Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. Adv Drug Deliv Rev. 2008; 60(6) 717-733
20 Martinez M N, Amidon G L. A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals. J Clin Pharmacol. 2002; 42(6) 620-643
21 Löbenberg R, Amidon G L. Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. Eur J Pharm Biopharm. 2000; 50(1) 3-12
22 Salama N N, Eddington N D, Fasano A. Tight junction modulation and its relationship to drug delivery. Adv Drug Deliv Rev. 2006; 58(1) 15-28
23 Wright E M. The passive permeability of the small intestine. Biomembranes. 1974; 4A 159-198
24 Oostendorp R L, Beijnen J H, Schellens J H. The biological and clinical role of drug transporters at the intestinal barrier. Cancer Treat Rev. 2009; 35(2) 137-147
25 Murakami T, Takano M. Intestinal efflux transporters and drug absorption. Expert Opin Drug Metab Toxicol. 2008; 4(7) 923-939
26 Heyman M, Crain-Denoyelle A M, Desjeux J F. Endocytosis and processing of protein by isolated villus and crypt cells of the mouse small intestine. J Pediatr Gastroenterol Nutr. 1989; 9(2) 238-245
27 Jain K K. Drug delivery systems—an overview. Methods Mol Biol. 2008; 437 1-50
28 Gomez-Orellana I. Strategies to improve oral drug bioavailability. Expert Opin Drug Deliv. 2005; 2(3) 419-433
29 Goldberg M, Gomez-Orellana I. Challenges for the oral delivery of macromolecules. Nat Rev Drug Discov. 2003; 2(4) 289-295
30 Aungst B J. Intestinal permeation enhancers. J Pharm Sci. 2000; 89(4) 429-442
31 Malkov D, Wang H Z, Dinh S, Gomez-Orellana I. Pathway of oral absorption of heparin with sodium N-[8-(2-hydroxybenzoyl)amino] caprylate. Pharm Res. 2002; 19(8) 1180-1184
32 Rivera T M, Leone-Bay A, Paton D R, Leipold H R, Baughman R A. Oral delivery of heparin in combination with sodium N-[8-(2-hydroxybenzoyl)amino]caprylate: pharmacological considerations. Pharm Res. 1997; 14(12) 1830-1834
33 Hauel N H, Nar H, Priepke H, Ries U, Stassen J M, Wienen W. Structure-based design of novel potent nonpeptide thrombin inhibitors. J Med Chem. 2002; 45(9) 1757-1766
34 Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos. 2008; 36(2) 386-399
35 des Rieux A, Fievez V, Garinot M, Schneider Y J, Préat V. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J Control Release. 2006; 116(1) 1-27
36 Vauthier C, Couvreur P. Nanomedicines: a new approach for the treatment of serious diseases. J Biomed Nanotechnol. 2007; 3 223-224
37 de la Fuente M, Csaba N, Garcia-Fuentes M, Alonso M J. Nanoparticles as protein and gene carriers to mucosal surfaces. Nanomed. 2008; 3(6) 845-857
38 Florence A T. Nanoparticle uptake by the oral route: fulfilling its potential?. Drug Discov Today. 2005; 2 75-81
39 Hyers T M, Hull R D, Weg J G. Antithrombotic therapy for venous thromboembolic disease. Chest. 1995; 108 335S-351S
40 Arbit E, Goldberg M, Gomez-Orellana I, Majuru S. Oral heparin: status review. Thromb J. 2006; 4 6
41 Agarwal R, Klein G F, Chaudhary K. Liquid heparin formulation. International patent application. , WO00134114
42 Mousa S A, Zhang F, Aljada A et al.. Pharmacokinetics and pharmacodynamics of oral heparin solid dosage form in healthy human subjects. J Clin Pharmacol. 2007; 47(12) 1508-1520
43 Berkowitz S D, Marder V J, Kosutic G, Baughman R A. Oral heparin administration with a novel drug delivery agent (SNAC) in healthy volunteers and patients undergoing elective total hip arthroplasty. J Thromb Haemost. 2003; 1(9) 1914-1919
44 Baughman R A, Kapoor S C, Agarwal R K, Kisicki J, Catella-Lawson F, FitzGerald G A. Oral delivery of anticoagulant doses of heparin. A randomized, double-blind, controlled study in humans. Circulation. 1998; 98(16) 1610-1615
45 Hull R D, Kakkar A K, Marder V J et al.. Oral SNAC–heparin vs. enoxaparin for preventing venous thromboembolism following total hip replacement. Blood. 2002; 100 148a , Abstract 558
46 Pineo G, Hull R, Marder V. Oral delivery of heparin: SNAC and related formulations. Best Pract Res Clin Haematol. 2004; 17(1) 153-160
47 Majuru S. Advances in the oral delivery of heparin from solid dosage forms using Emisphere's Eligenm^® Oral Drug Delivery Technology. Drug Deliv Technol. 2004; 4 84-89
48 Riley M G, Castelli M C, Paehler E A. Subchronic oral toxicity of salcaprozate sodium (SNAC) in Sprague-Dawley and Wistar rats. Int J Toxicol. 2009; 28(4) 278-293
49 Riley M G, York R G. Peri- and postnatal developmental toxicity of salcaprozate sodium (SNAC) in Sprague-Dawley rats. Int J Toxicol. 2009; 28(4) 266-277
50 Maher S, Leonard T W, Jacobsen J, Brayden D J. Safety and efficacy of sodium caprate in promoting oral drug absorption: from in vitro to the clinic. Adv Drug Del Rev. 2009; 61(15) 1427-1449
51 Leonard T W, Lynch J, McKenna M J, Brayden D J. Promoting absorption of drugs in humans using medium-chain fatty acid-based solid dosage forms: GIPET. Expert Opin Drug Deliv. 2006; 3(5) 685-692
52 Squier C A, Kremer M J. Biology of oral mucosa and esophagus. J Natl Cancer Inst Monogr. 2001; 29(29) 7-15
53 Modi P. Development of the RapidMist drug delivery system for the treatment of diabetes, cardiovascular diseases and breakthrough cancer pain. Drugs Fut. 2005; 30(3) 271-276
54 Panka J M inventor. Micellar pharmaceutical compositions for buccal and pulmonary application. European patent. , EP1261320
55 Bernstein G. Delivery of insulin to the buccal mucosa utilizing the RapidMist system. Expert Opin Drug Deliv. 2008; 5(9) 1047-1055
56 Motlekar N A, Youan B B. The quest for non-invasive delivery of bioactive macromolecules: a focus on heparins. J Control Release. 2006; 113(2) 91-101
57 Siekmeier R, Scheuch G. Systemic treatment by inhalation of macromolecules—principles, problems, and examples. J Physiol Pharmacol. 2008; 59(suppl 6) 53-79
58 Rao R, Nanda S. Sonophoresis: recent advancements and future trends. J Pharm Pharmacol. 2009; 61(6) 689-705
59 Yang T, Mustafa F, Bai S, Ahsan F. Pulmonary delivery of low molecular weight heparins. Pharm Res. 2004; 21(11) 2009-2016
60 Zhang Y J, Ma C H, Lu W L et al.. Permeation-enhancing effects of chitosan formulations on recombinant hirudin-2 by nasal delivery in vitro and in vivo. Acta Pharmacol Sin. 2005; 26(11) 1402-1408
61 Pacini S, Punzi T, Gulisano M, Cecchi F, Vannucchi S, Ruggiero M. Transdermal delivery of heparin using pulsed current iontophoresis. Pharm Res. 2006; 23(1) 114-120
62 Maggio E T. Compositions for drug administration. US patent application US2009047347A1
63 Yang T, Arnold J J, Ahsan F. Tetradecylmaltoside (TDM) enhances in vitro and in vivo intestinal absorption of enoxaparin, a low molecular weight heparin. J Drug Target. 2005; 13(1) 29-38
64 Arnold J, Ahsan F, Meezan E, Pillion D J. Nasal administration of low molecular weight heparin. J Pharm Sci. 2002; 91(7) 1707-1714
65 Clausen A E, Kast C E, Bernkop-Schnürch A. The role of glutathione in the permeation enhancing effect of thiolated polymers. Pharm Res. 2002; 19(5) 602-608
66 Kast C E, Guggi D, Langoth N, Bernkop-Schnürch A. Development and in vivo evaluation of an oral delivery system for low molecular weight heparin based on thiolated polycarbophil. Pharm Res. 2003; 20(6) 931-936
67 Kim S K, Lee D Y, Lee E et al.. Absorption study of deoxycholic acid-heparin conjugate as a new form of oral anti-coagulant. J Control Release. 2007; 120(1-2) 4-10
68 Hoffart V, Lamprecht A, Maincent P et al.. Oral bioavailability of low molecular weight heparin using polymeric delivery system. J Control Release. 2006; 113 38-42
69 Jiao Y, Ubrich N, Marchand-Arvier M et al.. In vitro and in vivo evaluation of oral heparin-loaded polymeric nanoparticles in rabbits. Circulation. 2002; 105(2) 230-235
70 Chen M C, Wong H S, Lin K J et al.. The characteristics, biodistribution and bioavailability of a chitosan-based nanoparticulate system for the oral delivery of heparin. Biomaterials. 2009; 30(34) 6629-6637
71 Scala-Bertola J, Rabiskova M, Lecompte T, Bonneaux F, Maincent P. Granules in the improvement of oral heparin bioavailability. Int J Pharm. 2009; 374(1-2) 12-16
72 Motlekar N A, Srivenugopal K S, Wachtel M S, Youan B B. Evaluation of the oral bioavailability of low molecular weight heparin formulated with glycyrrhetinic acid as permeation enhancer. Drug Dev Res. 2006; 67(2) 166-174
73 Hoffart V, Lamprecht A, Maincent P, Lecompte T, Vigneron C, Ubrich N. Oral bioavailability of a low molecular weight heparin using a polymeric delivery system. J Control Release. 2006; 113(1) 38-42
74 Lanke S S, Gayakwad S G, Strom J G, D’souza M J. Oral delivery of low molecular weight heparin microspheres prepared using biodegradable polymer matrix system. J Microencapsul. 2009; 26(6) 493-500
75 Grabovac V, Schmitz T, Föger F, Bernkop-Schnürch A. Papain: an effective permeation enhancer for orally administered low molecular weight heparin. Pharm Res. 2007; 24(5) 1001-1006
76 Motlekar N A, Fasano A, Wachtel M S, Youan B B. Zonula occludens toxin synthetic peptide derivative AT1002 enhances in vitro and in vivo intestinal absorption of low molecular weight heparin. J Drug Target. 2006; 14(5) 321-329
77 Motlekar N A, Srivenugopal K S, Wachtel M S, Youan B B. Modulation of gastrointestinal permeability of low-molecular-weight heparin by L-arginine: in-vivo and in-vitro evaluation. J Pharm Pharmacol. 2006; 58(5) 591-598
78 Ito Y, Kusawake T, Prasad Y V, Sugioka N, Shibata N, Takada K. Preparation and evaluation of oral solid heparin using emulsifier and adsorbent for in vitro and in vivo studies. Int J Pharm. 2006; 317(2) 114-119
79 Lee Y K, Kim S K, Lee D Y et al.. Efficacy of orally active chemical conjugate of low molecular weight heparin and deoxycholic acid in rats, mice and monkeys. J Control Release. 2006; 111(3) 290-298
80 Motlekar N A, Srivenugopal K S, Wachtel M S, Youan B B. Oral delivery of low-molecular-weight heparin using sodium caprate as absorption enhancer reaches therapeutic levels. J Drug Target. 2005; 13(10) 573-583
81 Kim S K, Lee E H, Vaishali B et al.. Tricaprylin microemulsion for oral delivery of low molecular weight heparin conjugates. J Control Release. 2005; 105(1-2) 32-42
82 Kim S K, Vaishali B, Lee E et al.. Oral delivery of chemical conjugates of heparin and deoxycholic acid in aqueous formulation. Thromb Res. 2006; 117(4) 419-427
83 Yang T, Arnold J J, Ahsan F. Tetradecylmaltoside (TDM) enhances in vitro and in vivo intestinal absorption of enoxaparin, a low molecular weight heparin. J Drug Target. 2005; 13(1) 29-38
84 Schmitz T, Leitner V M, Bernkop-Schnürch A. Oral heparin delivery: design and in vivo evaluation of a stomach-targeted mucoadhesive delivery system. J Pharm Sci. 2005; 94(5) 966-973
85 Kast C E, Guggi D, Langoth N, Bernkop-Schnürch A. Development and in vivo evaluation of an oral delivery system for low molecular weight heparin based on thiolated polycarbophil. Pharm Res. 2003; 20(6) 931-936
86 Lee Y, Nam J H, Shin H C, Byun Y. Conjugation of low-molecular-weight heparin and deoxycholic acid for the development of a new oral anticoagulant agent. Circulation. 2001; 104(25) 3116-3120
87 Lamprecht A, Ubrich N, Maincent P. Oral low molecular weight heparin delivery by microparticles from complex coacervation. Eur J Pharm Biopharm. 2007; 67(3) 632-638
88 Kim S K, Lee D Y, Lee E et al.. Absorption study of deoxycholic acid-heparin conjugate as a new form of oral anti-coagulant. J Control Release. 2007; 120(1-2) 4-10
89 Jiao Y, Ubrich N, Marchand-Arvier M et al.. In vitro and in vivo evaluation of oral heparin-loaded polymeric nanoparticles in rabbits. Circulation. 2002; 105(2) 230-235
90 Lee Y, Kim S H, Byun Y. Oral delivery of new heparin derivatives in rats. Pharm Res. 2000; 17(10) 1259-1264
91 Cen X, Ni J, Tan T et al.. Investigation on recombinant hirudin via oral route. Peptides. 2006; 27(4) 836-840

Luka PeternelPh.D.

SDC Slovenia, Lek Pharmaceuticals d.d.

Verovškova 57, 1526 Ljubljana, Slovenia

Email: luka.peternel@sandoz.com